WO2004092207A3 - Respiratory syncytial virus (rsv) peptides - Google Patents

Respiratory syncytial virus (rsv) peptides Download PDF

Info

Publication number
WO2004092207A3
WO2004092207A3 PCT/EP2004/004061 EP2004004061W WO2004092207A3 WO 2004092207 A3 WO2004092207 A3 WO 2004092207A3 EP 2004004061 W EP2004004061 W EP 2004004061W WO 2004092207 A3 WO2004092207 A3 WO 2004092207A3
Authority
WO
WIPO (PCT)
Prior art keywords
peptides
rsv
respiratory syncytial
syncytial virus
vaccines
Prior art date
Application number
PCT/EP2004/004061
Other languages
French (fr)
Other versions
WO2004092207A2 (en
Inventor
Ignace Lasters
Johan Desmet
Toon Stegmann
Original Assignee
Algonomics N V
Ignace Lasters
Johan Desmet
Toon Stegmann
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Algonomics N V, Ignace Lasters, Johan Desmet, Toon Stegmann filed Critical Algonomics N V
Publication of WO2004092207A2 publication Critical patent/WO2004092207A2/en
Publication of WO2004092207A3 publication Critical patent/WO2004092207A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56977—HLA or MHC typing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The present invention relates to peptides which are suitable for inducing an immune response to RSV and to the use of said peptides for the preparations of vaccines, compositions and in methods of diagnosis.
PCT/EP2004/004061 2003-04-16 2004-04-16 Respiratory syncytial virus (rsv) peptides WO2004092207A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03447095.5 2003-04-16
EP03447095 2003-04-16

Publications (2)

Publication Number Publication Date
WO2004092207A2 WO2004092207A2 (en) 2004-10-28
WO2004092207A3 true WO2004092207A3 (en) 2005-04-07

Family

ID=33186034

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2004/004061 WO2004092207A2 (en) 2003-04-16 2004-04-16 Respiratory syncytial virus (rsv) peptides

Country Status (1)

Country Link
WO (1) WO2004092207A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1840133A1 (en) * 2006-03-29 2007-10-03 Global Biotech Development Corp. Ltd. New immunomodulating oligopeptides
FR2903305B1 (en) * 2006-07-07 2012-06-01 Soc Extraction Principes Actif USE OF PLANT EXTRACTS AS SLIMMING ACTIVE INGREDIENTS
JP2010534057A (en) 2007-03-06 2010-11-04 シムフォゲン・アクティーゼルスカブ Recombinant antibody for treating respiratory syncytial virus infection
GB0823366D0 (en) 2008-12-22 2009-01-28 Uni I Oslo Synthesis
MX2013002303A (en) * 2010-09-07 2013-10-28 Oncotherapy Science Inc Ttll4 peptides and vaccines containing the same.
ES2657470T3 (en) 2012-03-20 2018-03-05 Humabs Biomed S.A. Antibodies that neutralize RSV, MPV and PVM and their uses
KR102119197B1 (en) * 2018-04-23 2020-06-05 주식회사 엘베이스 Composition for autophagy inhibiting in cell, And pharmaceutical composition for preventing or treating tumor disease, or inhibiting anti-cancer agents resistance containing the same

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994020127A1 (en) * 1993-03-05 1994-09-15 Cytel Corporation Hla-a2.1 binding peptides and their uses
WO1999014334A1 (en) * 1997-09-19 1999-03-25 American Cyanamid Company Peptides derived from the attachment (g) protein of respiratory syncytial virus

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994020127A1 (en) * 1993-03-05 1994-09-15 Cytel Corporation Hla-a2.1 binding peptides and their uses
WO1999014334A1 (en) * 1997-09-19 1999-03-25 American Cyanamid Company Peptides derived from the attachment (g) protein of respiratory syncytial virus

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DE GROOT, A.S. ET AL.: "Immuno-informatics: Mining genomes for vaccine components", IMMUNOLOGY AND CELL BIOLOGY, vol. 80, no. 3, June 2002 (2002-06-01), pages 255 - 269, XP002254696 *
HSU, S.-C. ET AL.: "Reduction of Respiratory Syncytial Virus Titer in the Lungs of Mice after Intranasal Immunization with a Chimeric Peptide Consisting of a Single CTL Epitope Linked to a Fusion Peptide", VIROLOGY, vol. 240, no. 2, 20 January 1998 (1998-01-20), pages 376 - 381, XP002254698 *
HUSSELL, T. ET AL.: "CD8+ T cells control Th2-driven pathology during pulmonary respiratory syncytial virus infection", EUROPEAN JOURNAL OF IMMUNOLOGY, vol. 27, no. 12, December 1997 (1997-12-01), pages 3341 - 3349, XP008035228 *
KULKARNI, A.B. ET AL.: "Cytotoxic T Cells Specific for a Single Peptide on the M2 Protein of Respiratory Syncytial Virus Are the Sole Mediators of Resistence Induced by Immunization with M2 Encoded by a Recombinant Vaccinia Virus", JOURNAL OF VIROLOGY, vol. 69, no. 2, February 1995 (1995-02-01), pages 1261 - 1264, XP002254697 *
MELERO, J.A. ET AL.: "Antigenic structure, evolution and immunobiology of the human respiratory syncytial virus attachment (G) protein", JOURNAL OF GENERAL VIROLOGY, vol. 78, no. 10, October 1997 (1997-10-01), pages 2411 - 2418, XP001018065 *

Also Published As

Publication number Publication date
WO2004092207A2 (en) 2004-10-28

Similar Documents

Publication Publication Date Title
WO2004075829A3 (en) Adjuvanted influenza vaccine
WO2006034292A3 (en) Antibodies against and methods for producing vaccines for respiratory syncytial virus
WO2004014418A3 (en) Neisserial vaccine compositions comprising a combination of antigens
WO2008061243A3 (en) Respiratory syncytial virus-virus like particle (vlps)
EP4219566A3 (en) Recombinant rsv antigens
WO2006038908A3 (en) Ancestral and cot viral sequences, proteins and immunogenic compositions
WO2006113214A3 (en) Vaccine against pandemic strains of influenza viruses
WO2006068663A3 (en) Vaccine compositions for treating coronavirus infection
WO2005089164A3 (en) Inducing cellular immune responses to human papillomavirus using peptide and nucleic acid compositions
WO2007008918A3 (en) Virus vaccines comprising envelope-bound immunomodulatory proteins and methods of use thereof
PT1409692E (en) Novel peptides of the respiratory syncytial virus (rsv) g protein and their use in a vaccine
WO2004080403A3 (en) Influenza virus vaccine
WO2006115843A3 (en) Nipah virus vaccines
WO2010039224A3 (en) Respiratory syncytial virus (rsv) sequences for protein expression and vaccines
IL189313A0 (en) Virus-like particles as vaccines for paramyxovirus
WO2006020773A3 (en) Methods for preparing freeze-dried platelets, compositions comprising freeze-dried platelets, and methods of use
WO2009105152A3 (en) Virus-like particles as vaccines for paramyxovirus
WO2002087494A3 (en) Novel vaccine
WO2005028496A3 (en) Vaccine for treatment and prevention of herpes simplex virus infection
WO2005007673A3 (en) Immunogenic peptides
WO2006007555A3 (en) Rotavirus antigens
WO2008024919A8 (en) Interferon antagonists, antibodies thereto, and associated methods of use
WO2005058349A3 (en) Vaccine comprising il-12 or il-23 for treatment of autoimmune diseases
WO2002077012A3 (en) Human papilloma virus immunoreative peptides
WO2004092207A3 (en) Respiratory syncytial virus (rsv) peptides

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase